A phase i trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 4, 2010, Pages 791-801

  Jameson, Michael B ^a   Rischin, Danny ^b   Pegram, Mark ^c   Gutheil, John ^d   Patterson, Adam V ^e   Denny, William A ^e   Wilson, William R ^e  

^a WAIKATO HOSPITAL   (New Zealand)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Proacta Inc   (United States)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Dinitrobenzamide nitrogen mustard; Hypoxia; Phase I; PR 104; Prodrug

Indexed keywords

CORTICOSTEROID; MITOMYCIN C; PR 104; PRODRUG; UNCLASSIFIED DRUG; CHLORMETHINE DERIVATIVE; MULTIENZYME COMPLEX; PR-104;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; BONE MARROW SUPPRESSION; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHAGIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMOPTYSIS; HICCUP; HUMAN; HUMAN CELL CULTURE; HYPOXIA; INDIGESTION; INFECTION; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MOUTH PAIN; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PALMAR PLANTAR SYNDROME; PHASE 1 CLINICAL TRIAL; PNEUMONIA; POSITIONAL DIZZINESS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL; TUMOR CELL CULTURE; TUMOR VOLUME; VOMITING; WOUND PAIN; ANOXIA; AREA UNDER THE CURVE; CHEMICAL STRUCTURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOPLASM; NEUTROPENIA; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANOXIA; AREA UNDER CURVE; FATIGUE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MOLECULAR STRUCTURE; MULTIENZYME COMPLEXES; NEOPLASMS; NEUTROPENIA; NITROGEN MUSTARD COMPOUNDS; PRODRUGS; TREATMENT OUTCOME;

EID: 75749084473     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1188-1     Document Type: Article

References (58)

1. JM Brown AJ Giaccia 1998 The unique physiology of solid tumors: opportunities (and problems) for cancer therapy Cancer Res 58 1408 1416 1:STN:280:DyaK1c7ps1Ggsw%3D%3D 9537241
2. BG Wouters SA Weppler M Koritzinsky W Landuyt S Nuyts J Theys RK Chiu P Lambin 2002 Hypoxia as a target for combined modality treatments Eur J Cancer 38 240 257 10.1016/S0959-8049(01)00361-6 1:STN:280:DC%2BD38%2Fns1Omtw%3D%3D 11803141 (Pubitemid 34136999)
3. JM Brown WR Wilson 2004 Exploiting tumor hypoxia in cancer treatment Nature Rev Cancer 4 437 447 10.1038/nrc1367 1:CAS:528:DC%2BD2cXksVaisbs%3D
4. IF Tannock 1968 The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour Br J Cancer 22 258 273 1:STN:280:DyaF1czhvVGlsQ%3D%3D 5660132
5. AI Minchinton IF Tannock 2006 Drug penetration in solid tumours Nat Rev Cancer 6 583 592 10.1038/nrc1893 1:CAS:528:DC%2BD28XntFGlu7w%3D 16862189 (Pubitemid 44140857)
6. KO Hicks FB Pruijn TW Secomb MP Hay R Hsu JM Brown WA Denny MW Dewhirst WR Wilson 2006 Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs J Natl Cancer Inst 98 1118 1128 1:CAS:528:DC%2BD28Xotl2ktrg%3D 16912264
7. TG Graeber C Osmanian T Jacks DE Housman CJ Koch SW Lowe AJ Giaccia 1996 Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours Nature 379 88 91 10.1038/379088a0 1:CAS:528:DyaK28XivVKgug%3D%3D 8538748 (Pubitemid 26008141)
8. LH Gray 1957 Oxygenation in radiotherapy. I. Radiobiological considerations Br J Radiol 30 403 406 10.1259/0007-1285-30-356-403 1:CAS:528:DyaG2sXptFaisA%3D%3D 13446401
9. RH Thomlinson LH Gray 1955 The histological structure of some human lung cancers and possible implications for radiotherapy Br J Cancer 9 539 549 1:STN:280:DyaG28%2Fls1Gltg%3D%3D 13304213
10. BA Teicher JS Lazo AC Sartorelli 1981 Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells Cancer Res 41 73 81 1:CAS:528:DyaL3MXlvVCmug%3D%3D 7448778
11. KM Comerford TJ Wallace J Karhausen NA Louis MC Montalto SP Colgan 2002 Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene Cancer Res 62 3387 3394 1:CAS:528:DC%2BD38XkslWqsLc%3D 12067980
12. M Wartenberg FC Ling M Muschen F Klein H Acker M Gassmann K Petrat V Putz J Hescheler H Sauer 2003 Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species FASEB J 17 503 505 1:CAS:528: DC%2BD3sXitFaqurY%3D 12514119
13. G Raspaglio F Filippetti S Prislei R Penci I De Maria L Cicchillitti S Mozzetti G Scambia C Ferlini 2008 Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3′ flanking region Gene 409 100 108 10.1016/j.gene.2007.11.015 1:CAS:528:DC%2BD1cXnsl2nug%3D%3D 18178340
14. L Liu L Sun H Zhang Z Li X Ning Y Shi C Guo S Han K Wu D Fan 2009 Hypoxia-mediated up-regulation of MGr1-Ag/37LRP in gastric cancers occurs via hypoxia-inducible-factor 1-dependent mechanism and contributes to drug resistance Int J Cancer 124 1707 1715 10.1002/ijc.24135 1:CAS:528: DC%2BD1MXivVarsL8%3D 19123465
15. DM Brizel SP Scully JM Harrelson LJ Layfield JM Bean LR Prosnitz MW Dewhirst 1996 Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma Cancer Res 56 941 943 1:CAS:528:DyaK28XhtlKks7Y%3D 8640781
16. A Fyles M Milosevic D Hedley M Pintilie W Levin L Manchul RP Hill 2002 Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer J Clin Oncol 20 680 687 10.1200/JCO.20.3.680 1:STN:280:DC%2BD38%2Fpt1eguw%3D%3D 11821448 (Pubitemid 34111374)
17. AL Harris 2002 Hypoxia-a key regulatory factor in tumour growth Nature Rev Cancer 2 38 47 10.1038/nrc704 1:CAS:528:DC%2BD38XhvF2jtL4%3D
18. M Nordsmark J Alsner J Keller OS Nielsen OM Jensen MR Horsman J Overgaard 2001 Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations Br J Cancer 84 1070 1075 10.1054/bjoc.2001.1728 1:CAS:528:DC%2BD3MXktFymuro%3D 11308256 (Pubitemid 32448504)
19. P Subarsky RP Hill 2003 The hypoxic tumour microenvironment and metastatic progression Clin Exp Metastasis 20 237 250 10.1023/A:1022939318102 1:CAS:528:DC%2BD3sXisVGjtbw%3D 12741682 (Pubitemid 36513228)
20. SR McKeown RL Cowen KJ Williams 2007 Bioreductive drugs: from concept to clinic Clin Oncol 19 427 442 10.1016/j.clon.2007.03.006 1:STN:280: DC%2BD2szpsVSkug%3D%3D (Pubitemid 46995614)
21. JA Plumb M Gerritsen R Milroy P Thomson P Workman 1994 Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines Int J Radiat Oncol Biol Phys 29 295 299 1:CAS:528:DyaK2cXlt1Ckt7k%3D 8195022
22. BG Haffty LD Wilson YH Son EI Cho RJ Papac DB Fischer S Rockwell AC Sartorelli DA Ross CT Sasaki JJ Fischer 2005 Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial Int J Radiat Oncol Biol Phys 61 119 128 1:CAS:528:DC%2BD2MXjsVCl 15629602
23. AG van der Heijden PM Moonen EB Cornel H Vergunst TM de Reijke E van Boven EJ Barten R Puri CK van Kalken JA Witjes 2006 Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response J Urol 176 1349 1353 10.1016/j.juro.2006.06.007 16952629 (Pubitemid 44307194)
24. SY Sharp LR Kelland MR Valenti LA Brunton S Hobbs P Workman 2000 Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo Mol Pharmacol 58 1146 1155 1:CAS:528: DC%2BD3cXnslKgtLs%3D 11040064
25. RJ Knox F Friedlos T Marchbank JJ Roberts 1991 Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species Biochem Pharmacol 42 1691 1697 10.1016/0006-2952(91)90503-W 1:CAS:528:DyaK38XjsVSnsg%3D%3D 1930294
26. CM Celli N Tran R Knox AK Jaiswal 2006 NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs Biochem Pharmacol 72 366 376 10.1016/j.bcp.2006.04.029 1:CAS:528:DC%2BD28XmsFSltr0%3D 16765324 (Pubitemid 43975085)
27. G Chung-Faye D Palmer D Anderson J Clark M Downes J Baddeley S Hussain PI Murray P Searle L Seymour PA Harris D Ferry DJ Kerr 2001 Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954 Clin Cancer Res 7 2662 2668 1:CAS:528: DC%2BD3MXnsFSitrs%3D 11555577
28. Palmer DH, Mautner V, Mirza D, Oliff S, Gerritsen W, van dS, Jr, Hubscher S, Reynolds G, Bonney S, Rajaratnam R, Hull D, Horne M, Ellis J, Mountain A, Hill S, Harris PA, Searle PF, Young LS, James ND, Kerr DJ (2004) Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 22:1546-1552
29. PF Searle MJ Chen L Hu PR Race AL Lovering JI Grove C Guise M Jaberipour ND James V Mautner LS Young KJ Kerr A Mountain SA White EI Hyde 2004 Nitroreductase: a prodrug-activating enzyme for cancer gene therapy Clin Exp Pharmacol Physiol 31 811 816 10.1111/j.1440-1681.2004.04085.x 1:CAS:528:DC%2BD2cXhtVCjt73O 15566399 (Pubitemid 39556859)
30. J von Pawel R von Roemeling U Gatzemeier M Boyer LO Elisson P Clark D Talbot A Rey TW Butler V Hirsh I Olver B Bergman J Ayoub G Richardson D Dunlop A Arcenas R Vescio J Viallet J Treat 2000 Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors J Clin Oncol 18 1351 1359
31. Shepherd F, Koschel G, von Pawel J, Gatzmeier U, van Zandwiyk N, Woll P, van Klavren R, Krasko P, Desimone P, Nicolson M, Pieters W, Bigelow R, Rey A, Biallet J, Loh E (2000) Comparison of Tirazone (tirapazamine) and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): final results of the international phase III CATAPULT II Trial. Lung Cancer 29 (suppl 1):28, abstract 87
32. SK Williamson JJ Crowley PN Lara Jr J McCoy DH Lau RW Tucker GM Mills DR Gandara 2005 Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003 J Clin Oncol 23 9097 9104 10.1200/JCO.2005.01.3771 1:CAS:528:DC%2BD28Xnt1ygtw%3D%3D 16361616 (Pubitemid 46260164)
33. Rischin D, Peters L, O'Sullivan B, Giralt J, Yuen K, Trotti A, Bernier J, Bourhis J, Henke M, Fisher R (2008) Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 26:Abstract LBA6008
34. D Rischin RJ Hicks R Fisher D Binns J Corry S Porceddu LJ Peters Trans-Tasman Radiation Oncology Group 2006 Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2098 2104 10.1200/JCO.2005.05.2878 16648512 (Pubitemid 46622121)
35. WR Wilson KO Hicks SM Pullen DM Ferry NA Helsby AV Patterson 2007 Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards Radiat Res 167 625 636 10.1667/RR0807.1 1:CAS:528:DC%2BD2sXmtFKjtLg%3D 17523848 (Pubitemid 351292942)
36. CJ Koch 1993 Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin Cancer Res 53 3992 3997 1:CAS:528: DyaK3sXmt1SlsLg%3D 8358728
37. KO Hicks BG Siim FB Pruijn WR Wilson 2004 Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors Radiat Res 161 656 666 10.1667/RR3178 1:CAS:528:DC%2BD2cXksFGisL8%3D 15161354 (Pubitemid 39149574)
38. AE Lee WR Wilson 2000 Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice Toxicol Appl Pharmacol 163 50 59 10.1006/taap.1999.8834 1:CAS:528:DC%2BD3cXovValtA%3D%3D 10662604 (Pubitemid 30111976)
39. K Parmar P Mauch J Vergilio R Sackstein JD Down 2007 Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia Proc Natl Acad Sci USA 104 5431 5436 10.1073/pnas.0701152104 1:CAS:528: DC%2BD2sXkt1emtrY%3D 17374716 (Pubitemid 47175697)
40. NA Helsby SJ Wheeler FB Pruijn BD Palmer S Yang WA Denny WR Wilson 2003 Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2, 4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation Chem Res Toxicol 16 469 478 10.1021/tx025662b 1:CAS:528:DC%2BD3sXhs1Oksr4%3D 12703963 (Pubitemid 36514504)
41. AV Patterson DM Ferry SJ Edmunds Y Gu RS Singleton K Patel SM Pullen SP Syddall GJ Atwell S Yang WA Denny WR Wilson 2007 Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA crosslinking agent PR-104 Clin Cancer Res 13 3922 3932 10.1158/1078-0432.CCR-07-0478 1:CAS:528:DC%2BD2sXntFymt7w%3D 17606726 (Pubitemid 47037600)
42. KO Hicks H Myint AV Patterson FB Pruijn BG Siim K Patel WR Wilson 2007 Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine Int J Radiat Oncol Biol Phys 69 560 571 1:CAS:528:DC%2BD2sXhtVeqs7jI 17869669
43. RS Singleton CP Guise DM Ferry SM Pullen MJ Dorie JM Brown AV Patterson WR Wilson 2009 DNA crosslinks in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism and cytotoxicity Cancer Res 69 3884 3891 10.1158/0008-5472.CAN-08-4023 1:CAS:528: DC%2BD1MXltFOksLg%3D 19366798
44. K Patel D Lewiston Y Gu KO Hicks WR Wilson 2007 Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 856 302 311 10.1016/j.jchromb.2007.06.035 1:CAS:528:DC%2BD2sXpvFKgur8%3D 17644498 (Pubitemid 47302931)
45. CP Guise A Wang A Thiel D Bridewell WR Wilson AV Patterson 2007 Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia Biochem Pharmacol 74 810 820 10.1016/j.bcp.2007.06.014 1:CAS:528: DC%2BD2sXovFOjtrk%3D 17645874 (Pubitemid 47212075)
46. Y Gu AV Patterson GJ Atwell SB Chernikova JM Brown LH Thompson WR Wilson 2009 Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A Mol Cancer Ther 8 1714 1723 10.1158/1535-7163.MCT-08-1209 1:CAS:528:DC%2BD1MXntVKgt7g%3D 19509245
47. SC Liu GO Ahn M Kioi MJ Dorie AV Patterson JM Brown 2008 Optimised Clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA crosslinking agent PR-104 Cancer Res 68 7995 8003 10.1158/0008-5472.CAN-08-1698 1:CAS:528:DC%2BD1cXhtF2msLrP 18829557
48. Guise CP, Abbattista M, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Doñate F, Wilson WR, Patterson AV (2008) The bioreductive prodrug PR-104 is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res (in press)
49. TM Penning JE Drury 2007 Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms Arch Biochem Biophys 464 241 250 10.1016/j.abb.2007.04.024 1:CAS:528:DC%2BD2sXovFylt7g%3D 17537398 (Pubitemid 47214569)
50. K Wako T Kawasaki K Yamana K Suzuki S Jiang H Umezu T Nishiyama K Takahashi T Hamakubo T Kodama M Naito 2008 Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer J Clin Pathol 61 448 454 10.1136/jcp.2007.050906 1:CAS:528:DC%2BD1cXlsFegsbk%3D 17720776
51. K Ito H Utsunomiya T Suzuki S Saitou J Akahira K Okamura N Yaegashi H Sasano 2006 17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders (Review) Mol Cell Endocrinol 248 136 140 10.1016/j.mce.2005.11.038 1:CAS:528:DC%2BD28Xis1Wgtbs%3D 16406263
52. M Sakurai K Oishi K Watanabe 2005 Localization of cyclooxygenases-1 and -2, and prostaglandin F synthase in human kidney and renal cell carcinoma Biochem Biophys Res Commun 338 82 86 10.1016/j.bbrc.2005.08.194 1:CAS:528:DC%2BD2MXhtFyksrnO 16157291 (Pubitemid 41540540)
53. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M van Glabbeke AT Van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437 (Pubitemid 30099779)
54. GJ Atwell WA Denny 2007 Synthesis of 3H- and 2H4-labelled versions of the hypoxia-activated pre-prodrug 2-[(2-bromoethyl)-2, 4-dinitro-6-[[[2- (phosphonooxy)ethyl]amino]carbonyl]anilino]ethyl methanesulfonate (PR-104) J Labelled Comp Radiopharm 50 7 12 10.1002/jlcr.1147 1:CAS:528: DC%2BD2sXjvVOhsrw%3D (Pubitemid 46456784)
55. IF Tannock CM Lee JK Tunggal DS Cowan MJ Egorin 2002 Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy Clin Cancer Res 8 878 884 1:CAS:528: DC%2BD38XislOqurw%3D 11895922
56. LA Huxham AH Kyle JHE Baker LK Nykilchuk AI Minchinton 2004 Microregional effects of gemcitabine in HCT-116 xenografts Cancer Res 63 6537 6541 10.1158/0008-5472.CAN-04-0986 (Pubitemid 39297911)
57. J Birtwistle RE Hayden FL Khanim RM Green C Pearce NJ Davies N Wake H Schrewe JP Ride JK Chipman CM Bunce 2009 The aldo-keto reductase AKR1C3 contributes to 7, 12-dimethylbenz(a)anthracene-3, 4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis Mutat Res 662 67 74 1:CAS:528:DC%2BD1MXisFWqu7o%3D 19162045
58. MI Koukourakis SM Bentzen A Giatromanolaki GD Wilson FM Daley MI Saunders S Dische E Sivridis AL Harris 2006 Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial J Clin Oncol 24 727 735 10.1200/JCO.2005.02.7474 1:CAS:528:DC%2BD28XitVGisLk%3D 16418497 (Pubitemid 46622039)